ABSTRACT
The authors examined clinically and immunologically 60 patients with multiple sclerosis. One group (30 patients) received prednisolone in the complex treatment while the second group (30 patients) received only complex treatment. A control group of 20 healthy persons was examined. Patients of the first group showed marked neurological and immunological disorders which is considered as a complication due to the empiric prednisolone doses.
Subject(s)
Multiple Sclerosis/immunology , Prednisolone/administration & dosage , Antigen-Antibody Complex/blood , Central Nervous System Diseases/etiology , Central Nervous System Diseases/immunology , Chronic Disease , Combined Modality Therapy , Female , Humans , Immunoglobulins/blood , Immunoglobulins/drug effects , Male , Multiple Sclerosis/complications , Multiple Sclerosis/drug therapy , Prednisolone/adverse effectsABSTRACT
The authors examined the dynamics of IgA, IgM, IgG in the blood of 100 patients with multiple sclerosis. Of them 50 patients received complex treatment in combination with prednisolone. Comparison of indices of concentration of serum immunoglobulins revealed a distinct reduction of their level of all classes in patients with multiple sclerosis, especially in those receiving prednisolone. Prednisolone produced an unfavourable effect on the course of the demyelinating process in patients with multiple sclerosis.
Subject(s)
Immunoglobulins/analysis , Multiple Sclerosis/drug therapy , Prednisolone/therapeutic use , Adult , Antibody Formation/drug effects , Antibody Formation/immunology , Combined Modality Therapy , Humans , Multiple Sclerosis/immunology , Prednisolone/adverse effects , PrognosisABSTRACT
Changes of ATP-ase activity and accumulation of lipid peroxidation products in patients with multiple sclerosis depended on the clinical course of the disease. Exacerbation is accompanied by an increased activity of Mg2(+)-dependent ATP-ase and reduction of Ca2(+)-dependent ATP-ase in the leucocytes. These changes were not revealed during remission.
Subject(s)
Adenosine Triphosphatases/blood , Lipid Peroxidation , Multiple Sclerosis/blood , Adolescent , Adult , Erythrocytes/metabolism , Female , Humans , Leukocytes/metabolism , Lipid Peroxides/blood , Lipids/blood , Male , Middle AgedABSTRACT
Folic acid was used for the complex treatment of patients with multiple sclerosis. The doses employed were 200-300 mcg daily. It was established that folic acid improved the reparative processes in the gastric mucosa and produced a pronounced therapeutic effect on the neurological status of the patients, favoured improvement of their general condition.
